# Vir Biotechnology Inks $90 Million Gilead Deal to Develop T-Cell Engagers

- URL: https://stocks.freetheai.org/news/vir-biotechnology-inks-90-million-gilead-deal-to-develop-t-cell-engagers-b589da
- Published: 2026-10-14T12:30:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NASDAQ:VIR](https://stocks.freetheai.org/symbols/NASDAQ-VIR)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Vir Biotechnology, Inc. (VIR) has entered into a collaboration agreement with Gilead to discover three PRO-XTEN dual-masked T-cell engagers. Under the terms of the agreement, Vir Biotechnology, Inc. (VIR) receives $90 million upfront, consisting of $65 million in cash and $25 million in equity purchased at a 30% premium. Gilead receives an exclusive license for the resulting programs.

The agreement provides Vir Biotechnology, Inc. (VIR) with up to $45 million in near-term preclinical milestones and up to $1.74 billion in downstream development and commercial milestones, alongside tiered high single-digit to low double-digit royalties on future sales. The upfront capital and equity investment strengthen the company financial position, while validating its oncology platform and expansion into T-cell engager therapies. Shares of Vir Biotechnology, Inc. (VIR) were down 6.11% at $10.61 following the news.

Investors should monitor upcoming catalysts, including candidate nominations, preclinical progress that could trigger near-term milestone payments, and potential investigational new drug filings.

## Key points

- Vir Biotechnology, Inc. (VIR) partnered with Gilead to discover three PRO-XTEN dual-masked T-cell engagers.
- Vir receives $90 million upfront, including $65 million in cash and $25 million in equity at a 30% premium.
- The deal includes up to $45 million in near-term preclinical milestones and up to $1.74 billion in later milestones.
- Gilead receives exclusive licenses, while Vir is eligible for tiered high single-digit to low double-digit royalties.

## Questions and answers

### What are the financial terms of the Vir Biotechnology and Gilead deal?

Vir Biotechnology receives $90 million upfront ($65 million cash and $25 million equity at a 30% premium), up to $45 million in near-term preclinical milestones, up to $1.74 billion in downstream milestones, and tiered royalties. Gilead gains an exclusive license.

### How did Vir Biotechnology stock move after the Gilead agreement?

Vir Biotechnology, Inc. (VIR) stock fell 6.11% to $10.61 following the announcement.

### What are the next catalysts for Vir Biotechnology following this deal?

Key catalysts to watch include candidate nominations, preclinical progress that triggers milestone payments, and future investigational new drug filings or clinical data.